Published in Cancer Res on March 15, 2005
Epigenetic control of the foxp3 locus in regulatory T cells. PLoS Biol (2007) 7.86
Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing. Clin Cancer Res (2008) 3.09
Regulatory T-cell compartmentalization and trafficking. Blood (2006) 1.86
Increased regulatory and decreased CD8+ cytotoxic T cells in the blood of patients with idiopathic pulmonary arterial hypertension. Respiration (2007) 1.67
The development and function of regulatory T cells. Cell Mol Life Sci (2009) 1.66
OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis. J Exp Med (2009) 1.63
Expansion of effector memory regulatory T cells represents a novel prognostic factor in lower risk myelodysplastic syndrome. J Immunol (2012) 1.61
Immunological effects of low-dose cyclophosphamide in cancer patients treated with oncolytic adenovirus. Mol Ther (2011) 1.60
Epigenetic quantification of tumor-infiltrating T-lymphocytes. Epigenetics (2011) 1.57
De-regulation of common housekeeping genes in hepatocellular carcinoma. BMC Genomics (2007) 1.39
Selective recruitment of regulatory T cell through CCR6-CCL20 in hepatocellular carcinoma fosters tumor progression and predicts poor prognosis. PLoS One (2011) 1.34
Increased frequencies of T helper type 17 cells in the peripheral blood of patients with acute myeloid leukaemia. Clin Exp Immunol (2009) 1.30
Adjuvant therapy of melanoma with interferon: lessons of the past decade. J Transl Med (2008) 1.28
Increase in circulating Foxp3+CD4+CD25(high) regulatory T cells in nasopharyngeal carcinoma patients. Br J Cancer (2007) 1.26
Localisation pattern of Foxp3+ regulatory T cells is associated with clinical behaviour in gastric cancer. Br J Cancer (2007) 1.26
Pathways of distinction analysis: a new technique for multi-SNP analysis of GWAS data. PLoS Genet (2011) 1.24
Histone acetyltransferase mediated regulation of FOXP3 acetylation and Treg function. Curr Opin Immunol (2010) 1.23
Increase of CD4+ CD25+ regulatory T cells in the peripheral blood of patients with metastatic carcinoma: a Phase I clinical trial using cyclophosphamide and immunotherapy to eliminate CD4+ CD25+ T lymphocytes. Clin Exp Immunol (2007) 1.20
Higher frequencies of GARP(+)CTLA-4(+)Foxp3(+) T regulatory cells and myeloid-derived suppressor cells in hepatocellular carcinoma patients are associated with impaired T-cell functionality. Cancer Res (2013) 1.19
Analysis of circulating regulatory T cells in patients with metastatic prostate cancer pre- versus post-vaccination. Cancer Immunol Immunother (2010) 1.17
Immune checkpoint blockade in hepatocellular carcinoma: current progress and future directions. Hepatology (2014) 1.16
A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma. BMC Cancer (2010) 1.15
In situ analysis of FOXP3+ regulatory T cells in human colorectal cancer. J Transl Med (2006) 1.15
Regulatory T cells and human disease. Clin Dev Immunol (2007) 1.12
Regulatory T cells in human disease and their potential for therapeutic manipulation. Immunology (2006) 1.12
Direct ex vivo analysis of dendritic cells in patients with hepatocellular carcinoma. World J Gastroenterol (2006) 1.11
Tumor recognition and self-recognition induce distinct transcriptional profiles in antigen-specific CD4 T cells. J Immunol (2009) 1.07
Suppression, subversion and escape: the role of regulatory T cells in cancer progression. Clin Exp Immunol (2013) 1.06
The role of virus-induced regulatory T cells in immunopathology. Springer Semin Immunopathol (2006) 1.05
Increased prevalence of regulatory T cells in the tumor microenvironment and its correlation with TNM stage of hepatocellular carcinoma. J Cancer Res Clin Oncol (2010) 1.05
Potential plasticity of T regulatory cells in pancreatic carcinoma in relation to disease progression and outcome. Exp Ther Med (2012) 1.04
Phase I/II study of immunotherapy using tumor antigen-pulsed dendritic cells in patients with hepatocellular carcinoma. Int J Oncol (2012) 1.04
Disruption of TGF-beta signaling prevents the generation of tumor-sensitized regulatory T cells and facilitates therapeutic antitumor immunity. J Immunol (2009) 1.02
Tumor evasion from T cell surveillance. J Biomed Biotechnol (2011) 1.01
Homogeneous expansion of human T-regulatory cells via tumor necrosis factor receptor 2. Sci Rep (2013) 1.00
Liver immunology. Compr Physiol (2013) 0.99
Lymphocyte recruitment into the tumor site is altered in patients with MSI-H colon cancer. Fam Cancer (2009) 0.98
Tumor-induced impairment of TCR signaling results in compromised functionality of tumor-infiltrating regulatory T cells. J Immunol (2008) 0.98
Infiltrating regulatory T cell numbers is not a factor to predict patient's survival in oesophageal squamous cell carcinoma. Br J Cancer (2008) 0.97
Phenotypic and functional analysis of lymphocytes infiltrating osteolytic tumors: use as a possible therapeutic approach of osteosarcoma. BMC Cancer (2005) 0.96
Quantification of regulatory T cells in septic patients by real-time PCR-based methylation assay and flow cytometry. PLoS One (2012) 0.96
The influence of CD4+ CD25+ Foxp3+ regulatory T cells on the immune response to rotavirus infection. Vaccine (2008) 0.95
Frequencies and role of regulatory T cells in patients with (pre)malignant cervical neoplasia. Clin Exp Immunol (2007) 0.95
Cellular mediators of inflammation: tregs and TH17 cells in gastrointestinal diseases. Mediators Inflamm (2010) 0.94
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell (2017) 0.94
Natural Killer Cell-Based Therapies Targeting Cancer: Possible Strategies to Gain and Sustain Anti-Tumor Activity. Front Immunol (2015) 0.94
Hepatic stellate cells promote tumor progression by enhancement of immunosuppressive cells in an orthotopic liver tumor mouse model. Lab Invest (2013) 0.93
Role of lymphocytes in liver cancer. Oncoimmunology (2013) 0.93
The role of regulatory T cells in cancer. Immune Netw (2009) 0.93
Influence of serum and soluble CD25 (sCD25) on regulatory and effector T-cell function in hepatocellular carcinoma. Scand J Immunol (2010) 0.93
Hepatocellular carcinoma immunopathogenesis: clinical evidence for global T cell defects and an immunomodulatory role for soluble CD25 (sCD25). Dig Dis Sci (2010) 0.93
The polycomb group proteins, BMI-1 and EZH2, are tumour-associated antigens. Br J Cancer (2006) 0.92
The prognostic value of Foxp3+ tumor-infiltrating lymphocytes in patients with glioblastoma. J Neurooncol (2013) 0.91
Regulatory T cells are associated with post-cryoablation prognosis in patients with hepatitis B virus-related hepatocellular carcinoma. J Gastroenterol (2010) 0.90
Regulatory T-cell trafficking: from thymic development to tumor-induced immune suppression. Crit Rev Immunol (2010) 0.90
Regulatory T cells in human ovarian cancer. J Oncol (2012) 0.90
Serum level of CC-chemokine ligand 18 is increased in patients with non-small-cell lung cancer and correlates with survival time in adenocarcinomas. PLoS One (2012) 0.89
Targeting the inflammation in HCV-associated hepatocellular carcinoma: a role in the prevention and treatment. J Transl Med (2010) 0.88
FOXP3 expression and clinical characteristics of hepatocellular carcinoma. World J Gastroenterol (2010) 0.88
Hepatic stellate cells: central modulators of hepatic carcinogenesis. BMC Gastroenterol (2015) 0.86
Depletion of CD4(+)CD25(+) regulatory T cells can promote local immunity to suppress tumor growth in benzo[a]pyrene-induced forestomach carcinoma. World J Gastroenterol (2008) 0.85
Genetically modified T cells in cancer therapy: opportunities and challenges. Dis Model Mech (2015) 0.85
Behavior of circulating CD4+CD25+Foxp3+ regulatory T cells in colon cancer patients undergoing surgery. J Clin Immunol (2011) 0.85
Regulatory T cells in cancer immunotherapy. Cell Res (2016) 0.84
Prevalence of Foxp3 positive T regulatory cells is increased during progression of cutaneous squamous tumors. Yonsei Med J (2008) 0.84
Cellular immune suppressor mechanisms in patients with hepatocellular carcinoma. Dig Dis (2012) 0.84
Up-regulation of proliferative and migratory genes in regulatory T cells from patients with metastatic castration-resistant prostate cancer. Int J Cancer (2013) 0.84
Hepatocellular carcinoma and macrophage interaction induced tumor immunosuppression via Treg requires TLR4 signaling. World J Gastroenterol (2012) 0.84
Immunobiology of hepatocellular carcinoma. Langenbecks Arch Surg (2011) 0.84
Perioperative dynamic alterations in peripheral regulatory T and B cells in patients with hepatocellular carcinoma. J Transl Med (2012) 0.83
Liver transplantation for hepatocellular carcinoma: role of inflammatory and immunological state on recurrence and prognosis. World J Gastroenterol (2013) 0.83
Restoration of intrahepatic regulatory T cells through MMP-9/13-dependent activation of TGF-β is critical for immune homeostasis following acute liver injury. J Mol Cell Biol (2013) 0.83
Immunology of hepatocellular carcinoma. World J Hepatol (2015) 0.83
Alpha-fetoprotein specific CD4 and CD8 T cell responses in patients with hepatocellular carcinoma. World J Hepatol (2010) 0.83
Immunosuppressive effect of regulatory T lymphocytes in lung cancer, with special reference to their effects on the induction of autologous tumor-specific cytotoxic T lymphocytes. Oncol Lett (2012) 0.83
CD4+CD25+CD127(low) Regulatory T Cells Play Predominant Anti-Tumor Suppressive Role in Hepatitis B Virus-Associated Hepatocellular Carcinoma. Front Immunol (2015) 0.81
Influence of human immune cells on cancer: studies at the University of Colorado. Immunol Res (2013) 0.80
Roles of Tregs in development of hepatocellular carcinoma: a meta-analysis. World J Gastroenterol (2014) 0.80
Significant roles of regulatory T cells and myeloid derived suppressor cells in hepatitis B virus persistent infection and hepatitis B virus-related HCCs. Int J Mol Sci (2015) 0.80
Immunologic targeting of FOXP3 in inflammatory breast cancer cells. PLoS One (2013) 0.80
New roads open up for implementing immunotherapy in mesothelioma. Clin Dev Immunol (2012) 0.80
Telomere length in relation to immunological parameters in patients with renal cell carcinoma. PLoS One (2013) 0.80
A novel regulatory event-based gene set analysis method for exploring global functional changes in heterogeneous genomic data sets. BMC Genomics (2009) 0.79
Searching for the Achilles Heel of FOXP3. Front Oncol (2013) 0.79
Image analyzer-based assessment of tumor-infiltrating T cell subsets and their prognostic values in colorectal carcinomas. PLoS One (2015) 0.79
Higher FOXP3-TSDR demethylation rates in adjacent normal tissues in patients with colon cancer were associated with worse survival. Mol Cancer (2014) 0.79
Combination of SLC administration and Tregs depletion is an attractive strategy for targeting hepatocellular carcinoma. Mol Cancer (2013) 0.79
A novel T cell-based vaccine capable of stimulating long-term functional CTL memory against B16 melanoma via CD40L signaling. Cell Mol Immunol (2012) 0.79
The consequence of immune suppressive cells in the use of therapeutic cancer vaccines and their importance in immune monitoring. J Biomed Biotechnol (2011) 0.79
T cell receptor transgenic lymphocytes infiltrating murine tumors are not induced to express foxp3. J Hematol Oncol (2011) 0.79
Lessons learned from cancer vaccine trials and target antigen choice. Cancer Immunol Immunother (2016) 0.78
Comparison of circadian characteristics for cytotoxic lymphocyte subsets in non-small cell lung cancer patients versus controls. Clin Exp Med (2011) 0.78
Prospect of the use of checkpoint inhibitors in hepatocellular cancer treatments. Cancer Manag Res (2017) 0.78
The diverse roles of the TNF axis in cancer progression and metastasis. Trends Cancer Res (2016) 0.77
Substantially modified ratios of effector to regulatory T cells during chemotherapy in ovarian cancer patients return to pre-treatment levels at completion: implications for immunotherapy. Cancers (Basel) (2012) 0.77
Ganoderma lucidum polysaccharide extract inhibits hepatocellular carcinoma growth by downregulating regulatory T cells accumulation and function by inducing microRNA-125b. J Transl Med (2015) 0.77
Potentiality of immunotherapy against hepatocellular carcinoma. World J Gastroenterol (2015) 0.77
Clinical implications of basic research in hepatocellular carcinoma. J Hepatol (2015) 0.76
The Role of Indoleamine 2,3-Dioxygenase in Diethylnitrosamine-Induced Liver Carcinogenesis. PLoS One (2016) 0.76
Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 54.30
Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med (2011) 19.01
IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell (2004) 15.82
Telaprevir for previously treated chronic HCV infection. N Engl J Med (2010) 8.33
Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA (2012) 7.62
ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med (2014) 6.31
Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology (2003) 5.40
A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells. Gastroenterology (2008) 4.23
Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med (2007) 3.72
Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med (2014) 3.40
Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. Gastroenterology (2004) 3.19
Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study. Hepatology (2006) 3.18
Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology (2010) 3.02
Hepatocyte telomere shortening and senescence are general markers of human liver cirrhosis. FASEB J (2002) 2.96
Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus. Hepatology (2008) 2.80
Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med (2011) 2.72
Interleukin 6/gp130-dependent pathways are protective during chronic liver diseases. Hepatology (2003) 2.68
Autoimmune acute liver failure: proposed clinical and histological criteria. Hepatology (2011) 2.64
Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective. J Hepatol (2010) 2.58
Humanized mice for modeling human infectious disease: challenges, progress, and outlook. Cell Host Microbe (2009) 2.58
Myeloid-derived suppressor cells in inflammatory bowel disease: a new immunoregulatory pathway. Gastroenterology (2008) 2.56
Prospective biopsy-controlled evaluation of cell death biomarkers for prediction of liver fibrosis and nonalcoholic steatohepatitis. Hepatology (2011) 2.49
Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor. Hepatology (2009) 2.45
Myeloid derived suppressor cells in human diseases. Int Immunopharmacol (2011) 2.43
Hepatitis delta virus. Lancet (2011) 2.32
Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study. BMJ (2012) 2.32
MicroRNAs play a role in spontaneous recovery from acute liver failure. Hepatology (2014) 2.23
Deletion of IKK2 in hepatocytes does not sensitize these cells to TNF-induced apoptosis but protects from ischemia/reperfusion injury. J Clin Invest (2005) 2.20
Genetic predisposition and environmental danger signals initiate chronic autoimmune hepatitis driven by CD4+ T cells. Hepatology (2013) 2.12
Argyrin a reveals a critical role for the tumor suppressor protein p27(kip1) in mediating antitumor activities in response to proteasome inhibition. Cancer Cell (2008) 2.12
Microbiologic analysis of peri-pancreatic fluid collected during EUS in patients with pancreatitis: impact on antibiotic therapy. Gastrointest Endosc (2013) 2.10
Endoscopic vacuum-assisted closure of upper intestinal anastomotic leaks. Gastrointest Endosc (2008) 2.06
Outcome and quality of life in patients with polycystic liver disease after liver or combined liver-kidney transplantation. Liver Transpl (2006) 2.04
Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41. Gastroenterology (2008) 2.03
Multicentric evaluation of model for end-stage liver disease-based allocation and survival after liver transplantation in Germany--limitations of the 'sickest first'-concept. Transpl Int (2010) 1.99
The SCF-FBXW5 E3-ubiquitin ligase is regulated by PLK4 and targets HsSAS-6 to control centrosome duplication. Nat Cell Biol (2011) 1.99
Increased hepatotoxicity of tumor necrosis factor-related apoptosis-inducing ligand in diseased human liver. Hepatology (2007) 1.97
The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C. Hepatology (2012) 1.97
Hepatitis E virus (HEV)-specific T-cell responses are associated with control of HEV infection. Hepatology (2012) 1.94
The challenges in primary sclerosing cholangitis--aetiopathogenesis, autoimmunity, management and malignancy. J Hepatol (2008) 1.92
Management of major postsurgical gastroesophageal intrathoracic leaks with an endoscopic vacuum-assisted closure system. Gastrointest Endosc (2009) 1.89
Eligibility and safety of triple therapy for hepatitis C: lessons learned from the first experience in a real world setting. PLoS One (2013) 1.89
Skp2-dependent degradation of p27kip1 is essential for cell cycle progression. Genes Dev (2004) 1.88
Hepatitis B surface antigen quantification: why and how to use it in 2011 - a core group report. J Hepatol (2011) 1.86
Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis. Gut (2012) 1.86
A Direct in vivo RNAi screen identifies MKK4 as a key regulator of liver regeneration. Cell (2013) 1.86
Hepatic gas gangrene following liver transplantation. Liver Transpl (2007) 1.85
Interferon-alpha-induced TRAIL on natural killer cells is associated with control of hepatitis C virus infection. Gastroenterology (2010) 1.85
Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis. Nat Genet (2013) 1.83
Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue. J Hepatol (2010) 1.80
Regulation of accumulation and function of myeloid derived suppressor cells in different murine models of hepatocellular carcinoma. J Hepatol (2013) 1.80
The introduction of MELD-based organ allocation impacts 3-month survival after liver transplantation by influencing pretransplant patient characteristics. Transpl Int (2009) 1.78
Breaking tolerance to the natural human liver autoantigen cytochrome P450 2D6 by virus infection. J Exp Med (2008) 1.76
Hepatitis C virus infection affects the brain-evidence from psychometric studies and magnetic resonance spectroscopy. J Hepatol (2004) 1.76
Apoptosis of regulatory T lymphocytes is increased in chronic inflammatory bowel disease and reversed by anti-TNFα treatment. Gut (2011) 1.75
Coffee induces expression of glucuronosyltransferases by the aryl hydrocarbon receptor and Nrf2 in liver and stomach. Gastroenterology (2010) 1.75
Antigen-specific FoxP3-transduced T-cells can control established type 1 diabetes. Diabetes (2004) 1.73
Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naïve patients with a partial virological response. Hepatology (2011) 1.70
Glucocorticosteroids increase cell entry by hepatitis C virus. Gastroenterology (2010) 1.70
Genome-wide association analysis in primary sclerosing cholangitis. Gastroenterology (2009) 1.69
Prevalence and clinical associations of 10 defined autoantibodies in autoimmune polyendocrine syndrome type I. J Clin Endocrinol Metab (2004) 1.68
Hepatitis D virus infection--not a vanishing disease in Europe! Hepatology (2007) 1.68
Plasticity of human Th17 cells and iTregs is orchestrated by different subsets of myeloid cells. Blood (2011) 1.67
Telomerase gene mutations are associated with cirrhosis formation. Hepatology (2011) 1.67
The HEP-NET B/C co-infection trial: A prospective multicenter study to investigate the efficacy of pegylated interferon-alpha2b and ribavirin in patients with HBV/HCV co-infection. J Hepatol (2008) 1.65
Proteins induced by telomere dysfunction and DNA damage represent biomarkers of human aging and disease. Proc Natl Acad Sci U S A (2008) 1.65
Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection--a randomized trial. Gastroenterology (2013) 1.63
The IL-6-gp130-STAT3 pathway in hepatocytes triggers liver protection in T cell-mediated liver injury. J Clin Invest (2005) 1.63
Activity of the mTOR inhibitor RAD001, the dual mTOR and PI3-kinase inhibitor BEZ235 and the PI3-kinase inhibitor BKM120 in hepatocellular carcinoma. Liver Int (2013) 1.60
Prognostic implications of lactate, bilirubin, and etiology in German patients with acute liver failure. Clin Gastroenterol Hepatol (2008) 1.59
Advances in the diagnosis, pathogenesis, and management of autoimmune hepatitis. Gastroenterology (2010) 1.58
Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trial. Lancet Infect Dis (2013) 1.58